Investor

Relations

SEC Filings

Filing date	Form	Description	Filing Group	View
Nov 15, 2023	EFFECT	EFFECT	Other	View HTML 9999999995-23-003337.pdf 9999999995-23-003337.rtf 9999999995-23-003337.xls
Nov 07, 2023	8-K	Report of unscheduled material events or corporate event	Current Reports	View HTML 0000950170-23-059791.pdf 0000950170-23-059791.rtf 0000950170-23-059791.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Nov 07, 2023	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	View HTML 0000950170-23-059792.pdf 0000950170-23-059792.rtf 0000950170-23-059792.xls EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
Nov 07, 2023	S-3	Simplified registration form	Registration Statements	View HTML 0001193125-23-272415.pdf 0001193125-23-272415.rtf 0001193125-23-272415.xls
Oct 03, 2023	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-051393.pdf 0001209191-23-051393.rtf 0001209191-23-051393.xls
Sep 26, 2023	8-K	Report of unscheduled material events or corporate event	Current Reports	View HTML 0000950170-23-049928.pdf 0000950170-23-049928.rtf 0000950170-23-049928.xls EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Aug 11, 2023	SC 13D/A	An amendment to a SC 13D filing	Other	View HTML 0001193125-23-210724.pdf 0001193125-23-210724.rtf 0001193125-23-210724.xls
Aug 08, 2023	SC 13D/A	An amendment to a SC 13D filing	Other	View HTML 0001193125-23-205268.pdf 0001193125-23-205268.rtf 0001193125-23-205268.xls
Aug 08, 2023	8-K	Report of unscheduled material events or corporate event	Current Reports	View HTML 0000950170-23-039400.pdf 0000950170-23-039400.rtf 0000950170-23-039400.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
Aug 08, 2023	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	View HTML 0000950170-23-039408.pdf 0000950170-23-039408.rtf 0000950170-23-039408.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Data provided by Kaleidoscope.

Inozyme is a global leader in developing therapies for rare diseases.

321 Summer Street, Suite 400 Boston, MA 02210